134 related articles for article (PubMed ID: 33843428)
61. Bone-targeting nanoparticle to co-deliver decitabine and arsenic trioxide for effective therapy of myelodysplastic syndrome with low systemic toxicity.
Wu X; Hu Z; Nizzero S; Zhang G; Ramirez MR; Shi C; Zhou J; Ferrari M; Shen H
J Control Release; 2017 Dec; 268():92-101. PubMed ID: 29042320
[TBL] [Abstract][Full Text] [Related]
62. A novel all-trans retinoic acid derivative inhibits proliferation and induces apoptosis of myelodysplastic syndromes cell line SKM-1 cells via up-regulating p53.
Du Y; Li LL; Chen H; Wang C; Qian XW; Feng YB; Zhang L; Chen FH
Int Immunopharmacol; 2018 Dec; 65():561-570. PubMed ID: 30415163
[TBL] [Abstract][Full Text] [Related]
63. [Clinical significance of hypermethylation of DLC-1 gene in myelodysplastic syndrome patients and effects of decitabine on DLC-1 gene expression].
Fu HY; Zhou HR; Yan JG; Chen CJ; Shen JZ
Zhonghua Yi Xue Za Zhi; 2017 Feb; 97(6):412-417. PubMed ID: 28219126
[No Abstract] [Full Text] [Related]
64. Potential role of 5-aza-2'-deoxycytidine induced MAGE-A4 expression in immunotherapy for anaplastic thyroid cancer.
Gunda V; Cogdill AP; Bernasconi MJ; Wargo JA; Parangi S
Surgery; 2013 Dec; 154(6):1456-62; discussion 1462. PubMed ID: 24238058
[TBL] [Abstract][Full Text] [Related]
65. The cancer‑testis antigen NXF2 is activated by the hypomethylating agent decitabine in acute leukemia cells in vitro and in vivo.
Zhou J; Li Y; Yao Y; Wang L; Gao L; Gao X; Luo X; Li J; Jiang M; Zhou M; Wang L; Yu L
Mol Med Rep; 2013 Nov; 8(5):1549-55. PubMed ID: 24002123
[TBL] [Abstract][Full Text] [Related]
66. Decitabine activates specific caspases downstream of p73 in myeloid leukemia.
Tamm I; Wagner M; Schmelz K
Ann Hematol; 2005 Dec; 84 Suppl 1():47-53. PubMed ID: 16193303
[TBL] [Abstract][Full Text] [Related]
67. Transcriptional regulation of an axonemal central apparatus gene, sperm-associated antigen 6, by a SRY-related high mobility group transcription factor, S-SOX5.
Kiselak EA; Shen X; Song J; Gude DR; Wang J; Brody SL; Strauss JF; Zhang Z
J Biol Chem; 2010 Oct; 285(40):30496-505. PubMed ID: 20668334
[TBL] [Abstract][Full Text] [Related]
68. Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS.
Leone G; Voso MT; Teofili L; Lübbert M
Clin Immunol; 2003 Oct; 109(1):89-102. PubMed ID: 14585280
[TBL] [Abstract][Full Text] [Related]
69. Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms.
Ye XN; Zhou XP; Wei JY; Xu GX; Li Y; Mao LP; Huang J; Ren YL; Mei C; Wang JH; Lou YJ; Ma LY; Yu WJ; Ye L; Xie LL; Luo YW; Hu C; Niu LM; Dou MH; Jin J; Tong HY
Leuk Lymphoma; 2016; 57(6):1311-8. PubMed ID: 26372888
[TBL] [Abstract][Full Text] [Related]
70. Novel prodrugs of decitabine with greater metabolic stability and less toxicity.
Hattori N; Sako M; Kimura K; Iida N; Takeshima H; Nakata Y; Kono Y; Ushijima T
Clin Epigenetics; 2019 Aug; 11(1):111. PubMed ID: 31370878
[TBL] [Abstract][Full Text] [Related]
71. Induction of Foxp3 demethylation increases regulatory CD4+CD25+ T cells and prevents the occurrence of diabetes in mice.
Zheng Q; Xu Y; Liu Y; Zhang B; Li X; Guo F; Zhao Y
J Mol Med (Berl); 2009 Dec; 87(12):1191-205. PubMed ID: 19841877
[TBL] [Abstract][Full Text] [Related]
72. DNMT3A alterations associated with myeloid malignancies dictate differential responses to hypomethylating agents.
Casellas Román HL; Venugopal K; Feng Y; Shabashvili DE; Posada LM; Li J; Guryanova OA
Leuk Res; 2020 Jul; 94():106372. PubMed ID: 32445940
[No Abstract] [Full Text] [Related]
73. Changes in Apoptotic Pathways in MOLM-13 Cell Lines after Induction of Resistance to Hypomethylating Agents.
Janotka Ľ; Messingerová L; Šimoničová K; Kavcová H; Elefantová K; Sulová Z; Breier A
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669837
[TBL] [Abstract][Full Text] [Related]
74. Differential Histone Posttranslational Modifications Induced by DNA Hypomethylating Agents.
Malkaram SA; Shatnawi A; Fan J; Carraway H; Denvir J; Primerano DA; Abd Elmageed ZY; Fandy TE
Cancer Control; 2022; 29():10732748221074051. PubMed ID: 35067084
[TBL] [Abstract][Full Text] [Related]
75. Elevated fetal haemoglobin is a predictor of better outcome in MDS/AML patients receiving 5-aza-2'-deoxycytidine (Decitabine).
Lübbert M; Ihorst G; Sander PN; Bogatyreva L; Becker H; Wijermans PW; Suciu S; Bissé E; Claus R
Br J Haematol; 2017 Feb; 176(4):609-617. PubMed ID: 27905102
[TBL] [Abstract][Full Text] [Related]
76. Different mechanisms of drug resistance to hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukemia.
Šimoničová K; Janotka Ľ; Kavcová H; Sulová Z; Breier A; Messingerova L
Drug Resist Updat; 2022 Mar; 61():100805. PubMed ID: 35227933
[TBL] [Abstract][Full Text] [Related]
77. AICAR suppresses cell proliferation and synergizes with decitabine in myelodysplastic syndrome via DNA damage induction.
Liu J; Liang L; Li X; Peng YL; Zhang J; Wang XL; Liu J; Nie L
Biotechnol Lett; 2021 Jun; 43(6):1131-1142. PubMed ID: 33788127
[TBL] [Abstract][Full Text] [Related]
78. Clinical experience with decitabine in North American patients with myelodysplastic syndrome.
Yee KW; Jabbour E; Kantarjian HM; Giles FJ
Ann Hematol; 2005 Dec; 84 Suppl 1():18-24. PubMed ID: 16273408
[TBL] [Abstract][Full Text] [Related]
79. Decitabine and 5-azacitidine both alleviate LPS induced ARDS through anti-inflammatory/antioxidant activity and protection of glycocalyx and inhibition of MAPK pathways in mice.
Huang X; Kong G; Li Y; Zhu W; Xu H; Zhang X; Li J; Wang L; Zhang Z; Wu Y; Liu X; Wang X
Biomed Pharmacother; 2016 Dec; 84():447-453. PubMed ID: 27685787
[TBL] [Abstract][Full Text] [Related]
80. [Effect of Decitabine on Regulatory T Cells Relative Content in Peripheral Blood and Bone Marrow of Patients with Myelodysplastic Syndrome/Acute Myeloid Leukemia].
Hu R; Gao Y; Wen Y; Wu K; Duan C; Zeng Y; Shi MX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):36-42. PubMed ID: 35123601
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
